Dr. Paul R. Billings is the first Chief Medical Officer of LIFE Technologies, a world leader in providing nucleic acid and other analytic tools for biomedical research and the delivery of personalized medicine. Prior to joining LIFE, Dr. Billings was the founding and acting Director and Chief Scientific Officer of the Genomic Medicine Institute at El Camino Hospital in Mountain View, CA. From 2007-2009, Dr. Billings served as President, Chief Executive Officer and Director of CELLective Dx Corporation, a company sought to revolutionize cancer care through the provision of microfluidic products and services focused on circulating tumor cells. For five years until 2007, he was Senior Vice President and Senior Geneticist at Laboratory Corporation of America Holdings Inc (LH).Prior to joining LH, Dr. Billings was Deputy Chief of Staff and Chief of General Internal Medicine at the Palo Alto VA Healthcare System and Stanford Medical School, and then CMO and Deputy Network Director of VISN 17 in the Department of Veterans Affairs. Dr. Billings graduated with an AB in History summa cum laude from UC San Diego, received both his MD and PhD degrees from Harvard University.

Rowan Chapman joined MDV in 2001 to focus on life science investments. Her interests lie in the translation of complex data and technology to innovative products that impact drug and biofuel discovery, personalized medicine and healthcare decision making. Leveraging her business and technical experience as well as industry relationships she partners closely with entrepreneurs to help develop successful businesses in a "hands on" role to help get companies started and financed. She is a board member of iAccessCare and MLC Dx and a board observer at Artemis Health, Pacific Biosciences, Adamas Pharmaceuticals, ParAllele BioScience and Tethys Biosciences. Before MDV, Rowan held the position of director of business development at Rosetta Inpharmatics where she established collaborative partnerships with organizations in the pharmaceutical, agricultural and biotech fields as well as among various research institutions. Rowan holds a Ph.D. in cellular and molecular biology from the MRC Laboratory of Molecular Biology in Cambridge University, UK where she also earned a bachelor's degree with first class honors in Biochemistry. She served postdoctoral fellowships at the University of California, San Francisco, as well as at the MRC-Laboratory of Molecular Biology at Cambridge. Prior to her work in industry, she authored or co-authored more than a dozen articles and patents.

Dr. Engleman is a founding member of Vivo Ventures, LLC (formerly BioAsia Investments). He is Professor of Pathology and Medicine at Stanford University School of Medicine, where he oversees the Stanford Blood Center and his own immunology research group. An editor of numerous scientific journals and the inventor of multiple patented technologies, Dr. Engleman has authored more than 250 publications in medical and scientific journals and has trained more than 200 graduate students and postdoctoral fellows. He has co-founded a number of biopharmaceutical companies including Cetus Immune, Genelabs, National Medical Audit and Dendreon. He is the lead inventor of the technology underlying Provenge, Dendreon's cancer vaccine, which was shown to extend life for patients with metastatic prostate cancer with remarkably few side effects. Provenge is the first active immunotherapeutic agent to be approved by the FDA (in 2010).Dr. Engleman currently serves on the boards of several private biotechnology companies. He received his B.A. from Harvard University and his M.D. from Columbia University School of Medicine.

Melinda Richter is the founder and CEO of Prescience International, a firm dedicated to the commercialization of science and technology through consulting on, starting and managing research centers, incubators, foundations and institutes such as the San Jose BioCenter, the San Francisco Innovation Center, the San Diego BioCenter, the Seattle BioCenter, the Environmental Business Cluster (EBC), the UC Berkeley BioExec Institute. Prescience also provides commercialization services to key government research agencies like the National Cancer Institute and the California Energy Commission; in helping get their grantees investment. The San Jose BioCenter model, a science and technology incubator that provides specialized facilities, capital equipment, laboratory support and business development services to life science and cleantech companies, has the 2009 NBIA Randall Whaley Award for Best Incubator of the Year and also the 2009 NBIA Technology Incubator of the Year Award. In that regard, the BioCenter has become the best-practice model for many entities that wish to capitalize on innovation, ranging from economic development agencies to big corporate players. Ms. Richter currently sits on the governing board of the National Business Incubation Association and the boards of University of California Berkeley’s Haas School of Business BioExec Institute and San Jose State University’s Masters of Biotechnology Program. Ms. Richter holds a Bachelor of Commerce from the University of Saskatchewan in Canada and an M.B.A. from INSEAD in France.